Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
BigBear.ai Holdings
BBAI
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
AMGN Amgen
- 308.060
- +2.240+0.73%
Close Feb 28 16:00 ET
- 308.060
- 0.0000.00%
Post 20:01 ET
165.49BMarket Cap40.75P/E (TTM)
308.620High303.520Low3.17MVolume308.510Open305.820Pre Close974.70MTurnover0.59%Turnover Ratio40.75P/E (Static)537.20MShares338.97352wk High28.16P/B165.08BFloat Cap251.26952wk Low9.00Dividend TTM535.88MShs Float338.973Historical High2.92%Div YieldTTM1.67%Amplitude7.824Historical Low307.180Avg Price1Lot Size
Amgen Stock Forum
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR): A High-Growth Opportunity with Potential 10x Returns
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...
7
5
2
$Amgen (AMGN.US)$
AMGN, MRNA, PFE, JNJ ARE SAME BUS OR NOT = AMGN, MRNA, PFE, JNJ SEM BUT ZAY KO 🤔
AMGN, MRNA, PFE, JNJ ARE SAME BUS OR NOT = AMGN, MRNA, PFE, JNJ SEM BUT ZAY KO 🤔
Over the weekend, President Donald Trump announced tariffs on the U.S.'s top three trading partners—Canada, Mexico, and China—and threatened similar measures against the EU. On Monday, U.S. stocks experienced a selloff, with the major indices dropping. Losses narrowed, however, after news broke of a delay in imposing tariffs on Mexico.
Market worries over the tariffs focus on two key issues. U.S. companies that depend heavily ...
Market worries over the tariffs focus on two key issues. U.S. companies that depend heavily ...
44
4
94
$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
5
3
2
2
$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
11
2
4
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
14
1
4
No comment yet
HH1000 : but but this is lunr
Growth Investor27 HH1000 : $Esperion Therapeutics (ESPR.US)$ To the Moon. It has been sold hort & forced lower before an offer comes
HH1000 Growth Investor27 : i bought some calls for earnings a little while back. will see how that goes
72792912 : I no longer believe any positive rumors about this company
Rich2023 : Every day, some baseless rumors are spread.